{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:18:57Z","timestamp":1762017537046},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.amjopharm.2011.07.003","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T19:31:19Z","timestamp":1312486279000},"page":"224-233","source":"Crossref","is-referenced-by-count":18,"title":["Cytochrome P450 2D6 Phenotyping in an Elderly Population With Dementia and Response to Galantamine in Dementia: A Pilot Study"],"prefix":"10.1016","volume":"9","author":[{"given":"Jo-Anne","family":"Clarke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute I.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monidipa","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2011.07.003_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"Zanger","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","article-title":"The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment","volume":"72","author":"Brockmoller","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib4","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","article-title":"Codeine intoxication associated with ultrarapid CYP2D6 metabolism","volume":"351","author":"Gasche","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00228-007-0404-3","article-title":"Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)","volume":"64","author":"Goryachkina","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007691-200206000-00018","article-title":"Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion","volume":"24","author":"Guzey","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ageing\/afm117","article-title":"Cholinesterase inhibitors in dementia: yes, no, or maybe?","volume":"36","author":"Lemstra","year":"2007","journal-title":"Age Ageing"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/156720507781788846","article-title":"Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics","volume":"4","author":"Cacabelos","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","article-title":"Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients","volume":"62","author":"Varsaldi","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00008571-199912000-00001","article-title":"The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6","volume":"9","author":"Bachus","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2165\/00003088-200342150-00005","article-title":"Clinical pharmacokinetics of galantamine","volume":"42","author":"Farlow","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/dmd.30.5.553","article-title":"The metabolism and excretion of galantamine in rats, dogs, and humans","volume":"30","author":"Mannens","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.159","article-title":"Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition","volume":"50","author":"Bickel","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0731-7085(91)80203-L","article-title":"Determination of dextromethorphan and dextrorphan in urine by high-performance liquid chromatography after solid-phase extraction","volume":"9","author":"Wenk","year":"1991","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(84)92591-1","article-title":"Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism","volume":"2","author":"Kupfer","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/humu.10280","article-title":"CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR","volume":"22","author":"Schaeffeler","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/(SICI)1099-1166(199706)12:6<619::AID-GPS554>3.0.CO;2-H","article-title":"The Clock Drawing Test for dementia of the Alzheimer's type: a comparison of three scoring methods in a memory disorders clinic","volume":"12","author":"Brodaty","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib22","series-title":"Study Guide for Fundamentals of Biostatistics","author":"Rosner","year":"2000"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib23","author":"Flockhart"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/00498258609050249","article-title":"Pharmacogenetics of dextromethorphan O-demethylation in man","volume":"16","author":"Kupfer","year":"1986","journal-title":"Xenobiotica"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2011.07.003_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1353\/cja.2005.0052","article-title":"Pharmaceutical use among older adults: using administrative data to examine medication-related issues","volume":"24","author":"Metge","year":"2005","journal-title":"Can J Aging"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0002-9343(00)00451-4","article-title":"Incidence and preventability of adverse drug events in nursing homes","volume":"109","author":"Gurwitz","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1124\/dmd.105.003715","article-title":"Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm","volume":"33","author":"Ito","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00008571-200208000-00007","article-title":"Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment","volume":"12","author":"Rau","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","article-title":"Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes","volume":"10","author":"Streetman","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1099-1166(199705)12:5<567::AID-GPS552>3.0.CO;2-V","article-title":"Psychotropic drug use and cognitive decline among older men and women","volume":"12","author":"Dealberto","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib32","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.1073\/pnas.92.26.12260","article-title":"Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease","volume":"92","author":"Poirier","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib33","first-page":"147","article-title":"Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease","volume":"24","author":"Poirier","year":"1999","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib36","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/(SICI)1097-0258(20000615\/30)19:11\/12<1421::AID-SIM434>3.0.CO;2-P","article-title":"Measuring cognitive change in a cohort of patients with Alzheimer's disease","volume":"19","author":"Galasko","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S1041610200006359","article-title":"Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: a meta-analysis","volume":"12","author":"Han","year":"2000","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib38","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jalz.2007.11.010","article-title":"Current and future management of Alzheimer's disease","volume":"4","author":"Gauthier","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1017\/S031716710000216X","article-title":"Progress in clinical neurosciences: treatment of Alzheimer's disease and other dementias\u2014review and comparison of the cholinesterase inhibitors","volume":"29","author":"Hogan","year":"2002","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(05)62221-0","article-title":"Guidelines on drug treatments for Alzheimer's disease","volume":"350","author":"Lovestone","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2011.07.003_bib41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archneur.56.7.857","article-title":"Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease","volume":"56","author":"Clark","year":"1999","journal-title":"Arch Neurol"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154359461100119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154359461100119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T23:26:22Z","timestamp":1543620382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154359461100119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S154359461100119X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2011.07.003","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}